folfox+nivolumab+esophageal+nejm

2025-03-10 12:07:29

拼音 [ 拼音 ]

Camrelizumab Combined with FOLFOX4 Regimen as First-Line...

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. doi:10.1016/S0140-6736(17) 31046-2 15. Yau T, Hsu C, Kim TY, et al. Nivolumab in advanced ...
Camrelizumab Combined with FOLFOX4 Regimen as First-Line...

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. doi:10.1016/S0140-6736(17) 31046-2 15. Yau T, Hsu C, Kim TY, et al. Nivolumab in advanced ...